Palo Alto Investors’s Aldeyra Therapeutics ALDX Stock Holding History

Palo Alto Investors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$263K	Sell	155,709 -69,756	-31%	-$306K	0.04%	51
2025 Q4	$1.17M	Hold	225,465	–	–	0.16%	41
2025 Q3	$1.18M	Hold	225,465	–	–	0.22%	37
2025 Q2	$864K	Hold	225,465	–	–	0.18%	38
2025 Q1	$1.3M	Hold	225,465	–	–	0.25%	32
2024 Q4	$1.13M	Hold	225,465	–	–	0.17%	35
2024 Q3	$1.22M	Hold	225,465	–	–	0.16%	36
2024 Q2	$746K	Hold	225,465	–	–	0.09%	36
2024 Q1	$737K	Hold	225,465	–	–	0.08%	36
2023 Q4	$791K	Buy	225,465 +64,665	+40%	+$200K	0.07%	33
2023 Q3	$1.07M	Hold	160,800	–	–	0.1%	26
2023 Q2	$1.35M	Hold	160,800	–	–	0.11%	27
2023 Q1	$1.6M	Hold	160,800	–	–	0.13%	25
2022 Q4	$1.12M	Hold	160,800	–	–	0.1%	25
2022 Q3	$859K	Hold	160,800	–	–	0.07%	28
2022 Q2	$642K	Hold	160,800	–	–	0.06%	29
2022 Q1	$715K	Hold	160,800	–	–	0.06%	31
2021 Q4	$643K	Hold	160,800	–	–	0.04%	34
2021 Q3	$1.41M	Hold	160,800	–	–	0.09%	33
2021 Q2	$1.82M	Hold	160,800	–	–	0.1%	34
2021 Q1	$1.91M	Hold	160,800	–	–	0.11%	34
2020 Q4	$1.1M	Buy	160,800 +42,800	+36%	+$301K	0.06%	34
2020 Q3	$874K	Buy	118,000 +44,500	+61%	+$287K	0.05%	37
2020 Q2	$306K	Hold	73,500	–	–	0.02%	38
2020 Q1	$182K	Hold	73,500	–	–	0.02%	36
2019 Q4	$427K	Hold	73,500	–	–	0.02%	31
2019 Q3	$387K	Hold	73,500	–	–	0.03%	32
2019 Q2	$441K	Buy	+73,500	New	+$553K	0.02%	34

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Palo Alto Investors's ALDX Position: Q1 2026 in Review

Palo Alto Investors reduced its Aldeyra Therapeutics (ALDX) stake by 31% in Q1 2026, selling an estimated $306K and leaving 155,709 shares worth $263K. The position accounts for 0.04% of the portfolio, ranked #51.

Palo Alto Investors first reported a position in ALDX in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.91M in Q1 2021. 127 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Palo Alto Investors held 155,709 shares of Aldeyra Therapeutics worth $263K as of Q1 2026.
Palo Alto Investors sold 69,756 Aldeyra Therapeutics shares in Q1 2026, an estimated $306K.
Aldeyra Therapeutics made up 0.04% of Palo Alto Investors's portfolio in Q1 2026, its #51 holding.
Palo Alto Investors first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 28 quarters since.
Palo Alto Investors's Aldeyra Therapeutics position peaked at $1.91M in Q1 2021.
127 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.